SCWD Publications Digest

Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopeniaWasting Disorders

Home-Based Intervention to Prevent Functional Decline in (Pre)frail Older Adults: The PromeTheus Randomized Controlled Trial.

BACKGROUND

Older adults with (pre)frailty are vulnerable to deteriorations in physical functioning, mobility and independence. Evidence for frailty interventions utilizing existing services within primary healthcare structure is limited. The PromeTheus trial aimed to evaluate the effectiveness of a home-based, multifactorial, interdisciplinary...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHome-Based Intervention to Prevent Functional Decline in (Pre)frail Older Adults: The PromeTheus Randomized Controlled Trial.

Control of muscle mass during growth and aging: Clinical targets and pathways.

Muscle mass is a strong indicator of overall health in older adults. In healthy individuals, an adequate muscle mass is maintained through a balance between anabolic pathways, such as the mTOR pathway (mammalian target of rapamycin), and catabolic pathways, including...

📰 Journal: Best Practice & Research Clinical Endocrinology & Metabolism
Read MoreControl of muscle mass during growth and aging: Clinical targets and pathways.

A narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Cardiovascular-kidney-metabolic syndrome (CKMS) is a recently launched by American Heart Association to express the importance of interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system which has profound impacts on morbidity and mortality. The common pathologic processes...

📰 Journal: Clinical Nutrition
Read MoreA narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Muscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study.

BACKGROUND

Sarcopenia is inconsistently defined, and its definition might not adequately capture muscle failure, underlying disability, and other adverse outcomes in older adults. We aimed to develop and validate an evidence-based, outcome-driven model of muscle failure.

METHODS

In this derivation and multicohort validation...

Read MoreMuscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

MyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

BACKGROUND

Muscle atrophy occurs during physiological (i.e., fasting) and pathological conditions (i.e., cancer) and anticipates death. Since not all patients will undergo muscle wasting, it would be highly useful to identify them soon to intervene early. We aim to generate a...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyoRep: A Novel Reporter System to Detect Early Muscle Atrophy In Vitro and In Vivo.

Differential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and adipose tissue that is often resistant to nutritional support. The branched-chain amino acids (BCAA: leucine, isoleucine, and valine) stimulate protein synthesis, yet BCAA-targeted therapies have yielded...

📰 Journal: American Journal Of Physiology-Regulatory Integrative And Comparative Physiology
Read MoreDifferential Branched-Chain Amino Acid Metabolism in Tissues of Tumor-Bearing Male Mice.

Triglyceride-Glucose-Waist-to-Weight Index: Novel Biomarker for Mild Cognitive Impairment in Older People With Sarcopenic Obesity.

BACKGROUND

Sarcopenic obesity (SO) is closely associated with mild cognitive impairment (MCI). However, traditional body composition-based diagnostic criteria for SO fail to adequately incorporate insulin resistance, a key pathophysiological mechanism. This study aimed to investigate the association between SO, defined using...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTriglyceride-Glucose-Waist-to-Weight Index: Novel Biomarker for Mild Cognitive Impairment in Older People With Sarcopenic Obesity.

Discovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

Sarcopenia is a growing public health crisis with an unmet need for effective pharmacotherapies. Ligusticum chuanxiong (L. chuanxiong), commonly known as Chuanxiong in China, is a medicinal plant widely utilized for conditions involving muscle wasting and weakness. Herein, we report...

📰 Journal: Journal Of The American Chemical Society
Read MoreDiscovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

BACKGROUND AND AIMS

Sarcopenia is the accelerated loss of skeletal muscle mass and function associated with ageing. Sarcopenia screening consists of body composition imaging and physical function tests; however, these tests can be burdensome and inconsistent. This review aimed to synthesise...

📰 Journal: Archives Of Gerontology And Geriatrics
Read MoreThe diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

GDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

Metastasis and cancer-induced cachexia significantly reduce survivorship and quality of life for cancer patients. GDF10 (BMP3b) is a TGF-ß superfamily ligand with little knowledge of its role in cancer progression. Some studies have shown that GDF10 exerts tumor-suppressive effects in...

Read MoreGDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

PACS2 Alleviates Sepsis-Induced Myopathy by Activating ERK-MAPK Signalling Pathway to Suppress ER-Phagy.

BACKGROUND

Sepsis-induced myopathy (SIM) is a common and life-threatening complication, but its underlying mechanisms remain poorly understood. PACS2, a key resident protein at mitochondria-associated endoplasmic reticulum membranes (MAMs), regulates ER homeostasis under various pathological conditions. However, whether sepsis disrupts PACS2-dependent MAM...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MorePACS2 Alleviates Sepsis-Induced Myopathy by Activating ERK-MAPK Signalling Pathway to Suppress ER-Phagy.

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-β superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an...

📰 Journal: Experimental And Molecular Medicine
Read MoreDe novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

RAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

BACKGROUND

Cancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end-products (RAGE) is expressed by several cell types and sustains the inflammatory response in...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!